Concepedia

Author

Bernadette Johnson

Institute of Cancer Research

Also Known As

B. Johnson, B. M. Johnson, B.M. Johnson, Bernadette Johnson, Tiaan Jacobs

21

Publications

523

Citations

10

H-Index

15

Concepts

All Affiliations

Institute of Cancer ResearchRoyal Marsden HospitalRoyal Marsden NHS Foundation TrustUniversity of SouthamptonQueen's University Belfast
BJ

About

Bernadette Johnson is an author at Institute of Cancer Research specializing in medicine, oncology, and immunotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

178

2

Immunology

2

2

115

3

Pharmacology

1

1

14

4

Autoimmunity

1

1

97

5

Cancer Therapeutics

1

1

14

Bernadette Johnson

×

10

Publications

502

Citations

10

H-Index

YearCitations

A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of <sup>223</sup>Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases

Sarah Chittenden, Cécilia Hindorf, Christopher Parker,

Journal of Nuclear Medicine

2015

113

18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin)

Gary Cook, Chris Parker, Sue Chua,

EJNMMI Research

2011

112

DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8+ T-cell responses and increases PSA doubling time

Lindsey Chudley, Katy J. McCann, Ann Mander,

Cancer Immunology Immunotherapy

2012

97

Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy in Advanced Lymphoma: A Phase II Study

Vedang Murthy, Karen Thomas, Kerwyn Foo,

Clinical Lymphoma & Myeloma

2008

49

The utility of lactate dehydrogenase in the follow‐up of testicular germ cell tumours

Ramachandran Venkitaraman, Bernadette Johnson, Robert Huddart,

British Journal of Urology

2007

43

Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE)

Simon J. Crabb, Sarah Danson, James W.F. Catto,

Clinical Cancer Research

2021

24

Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival

Ana M. Denis-Bacelar, Sarah Chittenden, David P. Dearnaley,

European Journal of Nuclear Medicine and Molecular Imaging

2016

21

Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids

Niven Mehra, Adam Sharp, David Lorente,

Clinical Genitourinary Cancer

2017

18

P-497 ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: Results of the run-in phase of a two-part randomized Phase II study

J. Hevmach, Howard West, Robert O. Kerr,

Lung Cancer

2005

14

Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy

Ana M. Denis-Bacelar, Sarah Chittenden, V. R. McCready,

British Journal of Radiology

2018

11

Page 1